so, honestly, I find this bothersome. If they are focusing on lung, they knew the market sizes ahead of time, why spend the money on the trial? Why not, instead spend more on HNSCC and do a larger trial than the small trial size they did? They have good results in trials, but then the criticism and Immutep acknowledges, is that the trial sizes are small and may not be enough to prove efficacy or get early approval. Also, they came out and said that the HNSCC was skewed by the trial participants and the uneven distribution of those with HPV related cancer. Ok. Why didn’t they do a bigger trial size, fund it by not doing all the other ones. The prelim results from breast looked real good, now it’s just some side thing they aren’t focused on? This is their expertise and they have industry knowledge so they know better than me, or at least I hope they do. But, Why not use funds for fewer strong, solid trials and follow through on them?
IMM Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)